Evidence map›Paper›PMID 33526918›Full record

ArticleBone marrow transplantation2021

Predictors of hematologic malignancy relapse in patients with advanced chronic graft-versus-host disease.

Claire L Ruben, Filip Pirsl, Seth M Steinberg, Noa G Holtzman, Laura Parsons-Wandell, Judy Baruffaldi, Lauren M Curtis, Sandra A Mitchell, Ana Zelic Kerep, Edward W Cowen and 5 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00092235 (Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00092235 recruitingnot on this map

Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease

TypeobservationalSponsorNational Cancer Institute (NCI)Ran2004Enrolled650ConditionsChronic Graft vs. Host Disease
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Claire L RubenImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room CRC 4-3130, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0003-2845-4437
Filip PirslImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room CRC 4-3130, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0001-7919-0211
Seth M SteinbergBiostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 2W334, Bethesda, MD, 20850, USA.
Noa G HoltzmanImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room CRC 4-3130, Bethesda, MD, 20892, USA.
Laura Parsons-WandellImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room CRC 4-3130, Bethesda, MD, 20892, USA.
Judy BaruffaldiImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room CRC 4-3130, Bethesda, MD, 20892, USA.
Lauren M CurtisImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room CRC 4-3130, Bethesda, MD, 20892, USA.
Sandra A MitchellOutcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive MSC 9764, Bethesda, MD, 20892, USA.
Ana Zelic KerepImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room CRC 4-3130, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0001-9186-2586
Edward W CowenDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 12N240A, Bethesda, MD, 20892, USA.
Ann BergerPain and Palliative Care Service, National Institutes of Health Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0002-3764-0293
Galen O JoeRehabilitation Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Manuel B DatilesNational Eye Institute, National Institutes of Health, 31 Center Drive, Building 31, MSC 2510, Bethesda, MD, 20892, USA.
Jacqueline W MaysOral Immunobiology Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, 30 Convent Drive, Building 30 Room 301, MSC 4340, Bethesda, MD, 20892, USA.
Steven Z PavleticImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room CRC 4-3130, Bethesda, MD, 20892, USA. pavletis@mail.nih.gov.
National Institutes of Health · USNational Institutes of Health Clinical Center · US

Funding

Immunobiology and therapy of oral mucosal and salivary gland chronic graft-versus-host diseaseZIADE000747 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI MAYS, JACQUELINE · 2016 to 2025
$14.9M
Office of Collaborative BiostatisticsZIDSC007202 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI CHOO-WOSOBA, HYOYOUNG · 2009 to 2025
$14.5M
NIH Chronic GVHD Study GroupZIABC011743 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLETIC, STEVEN · 2016 to 2025
$10.2M
Chronic graft-versus-host diseaseZIABC011549 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI COWEN, EDWARD · 2014 to 2021
$5.2M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Malignancy relapse remains a major barrier to treatment success in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Chronic graft-versus-host disease (cGVHD) markedly reduces hematologic malignancy relapse risk, but relapses still occur in these patients. Patients (n = 275) with moderate or severe cGVHD were enrolled on the National Cancer Institute (NCI) prospective cross-sectional natural history study (NCT00092235). Subjects were median 36 months after allo-HSCT and were followed subsequently for malignancy relapse and survival. Seventeen patients experienced relapse. In a multivariable model including time-dependent influences on relapse, risk factors associated with increased risk of relapse included shorter time from transplant to cGVHD evaluation (HR 0.279, 95% CI 0.078-0.995) and lower number of prior lines of systemic immunosuppressive therapy for cGVHD (HR 0.260, 95% CI 0.094-0.719). In a model excluding time-dependent influences on relapse risk, lower number of prior lines of systemic immunosuppressive therapy for cGVHD (HR 0.288, 95% CI 0.103-0.804), lower C4 complement level (HR 0.346, 95% CI 0.129-0.923), and higher body mass index (HR 3.222, 95% CI 1.156-8.974), were all associated with increased relapse risk. Parameters indicating cGVHD severity and activity are associated with risk of malignancy relapse. Classical predictors of relapse after allo-HSCT do not seem to be prognostic.

Indexed as

Graft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationChronic DiseaseCross-Sectional StudiesHumansNeoplasm Recurrence, LocalProspective StudiesRetrospective Studies

Identifiers

PMID33526918
PMCPMC8555869
OpenAlexW3127579582

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.